<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04271969</url>
  </required_header>
  <id_info>
    <org_study_id>HFCWO-001</org_study_id>
    <nct_id>NCT04271969</nct_id>
  </id_info>
  <brief_title>Clinical Effectiveness Of High Frequency Chest Wall Oscillation (HFCWO) In A Bronchiectasis Population</brief_title>
  <acronym>HFCWO</acronym>
  <official_title>Clinical Effectiveness Of High Frequency Chest Wall Oscillation (HFCWO) In A Bronchiectasis Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Electromed, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Electromed, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to compare the patient's baseline QoL prior to HFCWO use against the&#xD;
      patient's QoL at various study timepoints over a one-year period of HFCWO use.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will use a prospective interventional comparative study design using the patient's&#xD;
      quality of life (QoL) as the primary study endpoint to determine HFCWO affect. The study will&#xD;
      compare the patient's QoL baseline (established at enrollment prior to HFCWO treatment) to&#xD;
      the QoL measured at various timepoints (enrollment, 2 months, 6 months and 12 months) over a&#xD;
      one-year period whilst receiving HFCWO treatment. In addition, a baseline for the secondary&#xD;
      endpoints will established at enrollment for comparison to measurements taken at various&#xD;
      timepoints over a one-year period whilst receiving HFCWO treatment. The patient's medical&#xD;
      records will be used to establish prior histories of exacerbation rates for comparison to&#xD;
      exacerbation rates experienced after one year of HFCWO treatment. Patients will serve as&#xD;
      their own control.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 18, 2020</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of Life (QoL): Quality of Life-Bronchiectasis (QOL-B) questionnaire</measure>
    <time_frame>1 year</time_frame>
    <description>The primary endpoint is the subject's quality of life (QoL) using the Quality of Life-Bronchiectasis (QOL-B) questionnaire as the measurement tool. QoL measured at enrollment (baseline) will be compared to QoL measured at 2 months, 6 months and 1 year.&#xD;
The previously validated questionnaire is titled &quot;Quality of Life Questionnaire - Bronchiectasis&quot;. The Likert style questionnaire asks the subject to subjectively rank their symptoms using a 4 scale base ranging from &quot;a lot of difficulty&quot; to &quot;no difficulty&quot; and &quot;always&quot; to &quot;never&quot;.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Measurements</measure>
    <time_frame>1 year</time_frame>
    <description>Exacerbation rates&#xD;
a. Pre HFCWO exacerbation rates will be established by review of the patient's medical records. Post HFCWO will recorded at 2 months, 6 months and 1 year.&#xD;
Exacerbation frequency&#xD;
The time to the subject's next exacerbation will be recorded for comparison pre to post HFCWO&#xD;
Lung function (FEV1, FVC, FEF25-75) measured by standard spirometry&#xD;
Sputum production measured by using the Breathlessness, Cough and Sputum Scale (BCSS) questionnaire&#xD;
Patient adherence to HFCWO treatment measured by SmartVest Connect wireless feature&#xD;
Six-minute walk test measured using American Thoracic Society standard test guidelines/protocol&#xD;
Radiographic changes compare patient's original high-resolution computerized tomography (HRCT) taken to initially</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Bronchiectasis</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SmartVest Airway Clearance System</intervention_name>
    <description>Pulmonary airway clearance of retained mucus via high frequency chest wall oscillation (SmartVest)</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Primary care clinic&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18 years of age or older&#xD;
&#xD;
          2. Previous diagnosis of bronchiectasis confirmed by HRCT within the last 6 months&#xD;
&#xD;
          3. Patients must have at least 6 months of medical records related to bronchiectasis&#xD;
&#xD;
          4. Patients must be stable and currently on a standard of care regimen for bronchiectasis&#xD;
             such as hypertonic saline and/or PEP&#xD;
&#xD;
          5. Patients with 1 or more exacerbations within the last 12 months&#xD;
&#xD;
          6. Previous and existing productive cough&#xD;
&#xD;
          7. No previous HFCWO use&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who are known to have cystic fibrosis&#xD;
&#xD;
          2. Patients who are known to have primary ciliary dyskinesia (PCD)&#xD;
&#xD;
          3. Patients with chronic obstructive pulmonary disease (COPD) without bronchiectasis&#xD;
&#xD;
          4. Patients breathing via an artificial airway&#xD;
&#xD;
          5. Severe bronchospasm based on exam or history&#xD;
&#xD;
          6. Any comorbidity(ies) or contraindications that would normally complicate tolerating&#xD;
             HFCWO treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Solomon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chet Sievert</last_name>
    <phone>651-246-8621</phone>
    <email>csievert@electromed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama - Birmingham (UAB University Hospital)</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233-2110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Solomon, MD</last_name>
      <phone>205-996-4975</phone>
      <email>gsolomon@uabmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Alexis Delbridge</last_name>
      <phone>205-934-9359</phone>
      <email>|adelbridge@uabmc.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colin Swenson, MD</last_name>
      <email>colin.swenson@emory.edu</email>
    </contact>
    <contact_backup>
      <last_name>Elizabeth Cox, CCMA</last_name>
      <phone>404-251-1705</phone>
      <email>elizabeth.m.cox@emory.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elliot Dasenbrook, MD</last_name>
      <email>dasenbe@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>David Weaver</last_name>
      <email>weaverd@ccf.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Tyler</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Philley, MD</last_name>
      <phone>903-877-7753</phone>
      <email>julie.philley@uthct.edu</email>
    </contact>
    <contact_backup>
      <last_name>Alicia Zavala</last_name>
      <phone>903-877-7890</phone>
      <email>alicia.zavala@uthct.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 13, 2020</study_first_submitted>
  <study_first_submitted_qc>February 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2020</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HFCWO</keyword>
  <keyword>Bronchiectasis</keyword>
  <keyword>SmartVest</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchiectasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

